Cargando…

How I treat refractory CRS and ICANS after CAR T-cell therapy

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly because of the expanding indications for standard-of-care treatment and the development of new investigational products. The establishment of consensus diagnostic criteria for cytokine release syndrome (CRS) and im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Michael D., Smith, Melody, Shah, Nirali N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Emergent Car T-Cell Toxicities
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329191/ https://www.ncbi.nlm.nih.gov/pubmed/36989488 http://dx.doi.org/10.1182/blood.2022017414

Ejemplares similares

How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023)

How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity
por: Santomasso, Bianca D., et al.
Publicado: (2023)

How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
por: Gutierrez, Cristina, et al.
Publicado: (2023)

Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions
por: Dalal, Prarthana J., et al.
Publicado: (2022)

Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation
por: Chen, Yunshuo, et al.
Publicado: (2021)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

Delay in COVID-19 Presentation in Patients Recently Treated with CD-19 Directed CAR-T Therapy
por: Wuliji, Natalie, et al.
Publicado: (2022)

Some Notes from the Olympia Motor Show
Publicado: (1919)

CAR-T-Zell-Therapie beim multiplen Myelom
por: Zhou, X., et al.
Publicado: (2021)

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
por: Wehrli, Marc, et al.
Publicado: (2022)

ICANS 8
por: Rutherford Appleton Laboratory. Chilton
Publicado: (1985)

ICANS 8
por: Rutherford Appleton Laboratory. Chilton
Publicado: (1985)

ICANS 8
por: Rutherford Appleton Laboratory. Chilton
Publicado: (1985)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy
por: Amin, Neha P., et al.
Publicado: (2018)

Did COVID-19 Push CAR-T to the Outpatient Setting?
por: Harris, Alyssa, et al.
Publicado: (2022)

Macrophage, the potential key mediator in CAR-T related CRS
por: Hao, Zhaonian, et al.
Publicado: (2020)

Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk
por: Wei, Zhenyu, et al.
Publicado: (2022)

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
por: Qi, Xingxing, et al.
Publicado: (2023)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Comparison of Humoral and T-Cell Response after Sars-Cov-2 Vaccination Among Patients before and after Chimeric Antigen Receptor-Modified T Cell (CAR-T cell) Therapy
por: Gonzalez, Michael A, et al.
Publicado: (2022)

Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
por: Wei, Zhenyu, et al.
Publicado: (2023)

DNA topoisomerase VIII: a novel subfamily of type IIB topoisomerases encoded by free or integrated plasmids in Archaea and Bacteria
por: Gadelle, Danièle, et al.
Publicado: (2014)

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
por: Bagri, Puneet Kumar, et al.
Publicado: (2014)

Radiotherapy-enhanced ototoxicity in elderly
por: Malgonde, Monika S., et al.
Publicado: (2014)

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities
por: Xiao, Canhua, et al.
Publicado: (2018)

Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data
por: Holyoake, Daniel L.P., et al.
Publicado: (2017)

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
por: Turicek, David P, et al.
Publicado: (2023)

ICANS prophylaxis: potentially transformative but elusive
por: Dowling, Mark R., et al.
Publicado: (2023)

How I treat adverse effects of CAR-T cell therapy
por: Yáñez, Lucrecia, et al.
Publicado: (2020)

Meaningful conversations in living with and treating chronic conditions: development of the ICAN discussion aid
por: Boehmer, Kasey R., et al.
Publicado: (2016)

GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes
por: Karhu, S. Tuuli, et al.
Publicado: (2020)

Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS
por: Masucci, Chiara, et al.
Publicado: (2023)

P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY
por: Yokoyama, Shota, et al.
Publicado: (2023)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

International Collaboration on Advanced Neutron Sources ICANS-X
Publicado: (1988)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
por: Zhang, Man, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_du1bgk3lco8vu4cje73uvq34c4